Signal Watch

One thing the market is pricing in that most people aren't talking about yet: A $170B patent cliff is bearing down on pharma.

A scramble it's triggering is inflating biotech valuations fast. The market is celebrating the dealmaking. It isn't yet pricing in what happens when the buying frenzy ends.

Why it matters before it becomes consensus:

→ More than 120 metabolic assets are currently in development across 60 companies. the GLP-1 pipeline alone is overcrowded. When pharma finishes plugging its patent holes, a long tail of unfunded assets will be left without a buyer and without a path.

→ Analysts expect 2026 to be one of the best investing opportunities in decades — but that consensus view is itself a warning sign. When everyone sees the same opportunity, valuation discipline disappears. The companies getting acquired today are setting price anchors for tomorrow's deals that may not hold.

Early signal or noise? Our read: Signal. The patent cliff is real, the M&A window is real — but the hangover comes when the strategic urgency fades and bloated valuations don't.